Drugs / Vutrisiran
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed AH amyloidosis 4 milestones | |||||
| Filed | Japan (PMDA) | AMVUTTRA | AH amyloidosis | 2025-02-13 | “Vutrisiran is currently under review for the treatment of ATTR-CM by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).” alnylam.com ↗ “Parallel filings for regulatory approval have also been submitted in all major regions, including Europe and Japan .” alnylam.com ↗ |
| Filed | EU (EMA) | AMVUTTRA | AH amyloidosis | 2024-10-16 | “the submission of a Type II Variation to the European Medicines Agency (EMA) for vutrisiran” alnylam.com ↗ |
| Filed | US (FDA) | AMVUTTRA | AH amyloidosis | 2024-10-09 | “the submission of its supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for vutrisiran” alnylam.com ↗ |
| Filed | US (FDA) | — | AH amyloidosis | 2022-04-04 | “Alnylam has identified a new facility to pack and label vutrisiran and submitted an amendment to the NDA for review by the FDA” alnylam.com ↗ |
| Filed familial amyloid neuropathy 1 milestone | |||||
| Filed | US (FDA) | — | familial amyloid neuropathy | 2021-04-29 | “accepted the Company’s New Drug Application (NDA) for vutrisiran, an investigational RNAi therapeutic for the treatment of the polyneuropathy of hereditary...” alnylam.com ↗ “Vutrisiran , a subcutaneously administered investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis Filed a NDA with the FDA.” alnylam.com ↗ “In June 2021 , the U.S. Food and Drug Administration (FDA) accepted the Company’s New Drug Application (NDA) submission for review for vutrisiran” alnylam.com ↗ “a New Drug Application (NDA) for the approval of vutrisiran was filed with the U.S. Food and Drug Administration (FDA) in April 2021” alnylam.com ↗ |
| Filed hereditary amyloidosis 1 milestone | |||||
| Filed | EU (EMA) | — | hereditary amyloidosis | 2021-09-13 | “today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vutrisiran” alnylam.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Label expansion | US (FDA) | AMVUTTRA | — | 2025-03-20 | fda.gov ↗ |
| Approved | EU (EMA) | Amvuttra | — | 2022-09-15 | europa.eu ↗ |
| Approved | US (FDA) | AMVUTTRA | — | 2022-06-13 | fda.gov ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 33 trials · 3 met primary | ||||||
| Phase 3 | NCT06679946 | Dec 2024 → Mar 2028 expected | — | Alnylam Pharmaceuticals | Enrolling by invitation | Met primary |
| Phase 3 | NCT04153149 | Nov 2019 → May 2024 overdue | — | Alnylam Pharmaceuticals | Active not recruiting | Met primary |
| Phase 3 | NCT03759379 | Feb 2019 → Nov 2020 | hereditary amyloidosis | Alnylam Pharmaceuticals | Completed | Met primary |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT02797847 Comparator | Jun 2016 → Jan 2018 | — | Alnylam Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT07223203 Comparator | Dec 2025 → Dec 2027 expected | familial amyloid neuropathy | Alnylam Pharmaceuticals | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 44
| Date | Issuer | Release |
|---|---|---|
| 2026-08-30 | Alnylam Pharmaceuticals | Results Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings alnylam.com ↗
The findings further reinforce the clinical profile of AMVUTTRA ® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. |
| 2026-07-30 | Alnylam Pharmaceuticals | Results Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress alnylam.com ↗
Presented New Data from HELIOS-B at Heart Failure 2026 Demonstrating Vutrisiran's Consistent Clinical Benefit Across Patient Populations |
| 2026-05-12 | Alnylam Pharmaceuticals | Results New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden alnylam.com ↗ |
| 2026-04-30 | Alnylam Pharmaceuticals | Results Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress alnylam.com ↗
New Data Presented at ACC.26 Further Support Use of Vutrisiran as First-Line Treatment for ATTR-CM |
| 2026-03-30 | Alnylam Pharmaceuticals | Results New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management alnylam.com ↗ |
| 2025-11-08 | Alnylam Pharmaceuticals | Results New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM alnylam.com ↗
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA ® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. |
| 2025-09-28 | Alnylam Pharmaceuticals | Results New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran alnylam.com ↗
Data from a post hoc analysis of the HELIOS-B study, which assessed whether treatment with vutrisiran was associated with a reduction in gastrointestinal (GI) adverse events in patients with ATTR-CM, compared to placebo, were presented during a late-breaking session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025 in Minneapolis, Minnesota . |
| 2025-08-31 | Alnylam Pharmaceuticals | Results New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM alnylam.com ↗
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA ® (vutrisiran), an RNAi therapeutic approved for the treatment |
| 2025-06-09 | Alnylam Pharmaceuticals | Regulatory Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy alnylam.com ↗
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication for its orphan RNAi therapeutic AMVUTTRA ® (vutrisiran). |
| 2025-05-17 | Alnylam Pharmaceuticals | Results AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B alnylam.com ↗
The results demonstrate that vutrisiran, which rapidly knocks down transthyretin, reduces key cardiovascular (CV) events such as CV hospitalizations, and heart failure (HF) hospitalizations. |
| 2025-04-28 | Alnylam Pharmaceuticals | Regulatory Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy alnylam.com ↗
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of its RNAi therapeutic vutrisiran for the treatment of wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). |
| 2025-03-29 | Alnylam Pharmaceuticals | Results Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025 alnylam.com ↗
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark HELIOS-B Phase 3 clinical trial, which evaluated vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) in a population representative of today’s patients. |
| 2025-03-20 | Alnylam Pharmaceuticals | Regulatory Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) alnylam.com ↗ |
| 2025-02-13 | Alnylam Pharmaceuticals | Regulatory Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress alnylam.com ↗
The FDA has accepted the sNDA and set an action goal date of March 23, 2025 , under the Prescription Drug User Fee Act (PDUFA). |
| 2024-11-25 | Alnylam Pharmaceuticals | Regulatory Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy alnylam.com ↗ |
| 2024-10-31 | Alnylam Pharmaceuticals | Regulatory Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity alnylam.com ↗
We’re pleased to have submitted regulatory filings in the U.S. and EU, keeping us on track for a potential U.S. launch in early 2025 and other markets later in the year, |
| 2024-10-16 | Alnylam Pharmaceuticals | Regulatory Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy alnylam.com ↗ |
| 2024-10-09 | Alnylam Pharmaceuticals | Regulatory Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy alnylam.com ↗ |
| 2024-09-29 | Alnylam Pharmaceuticals | Results Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 alnylam.com ↗ |
| 2024-08-30 | Alnylam Pharmaceuticals | Results Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress alnylam.com ↗
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). |
| 2024-08-01 | Alnylam Pharmaceuticals | Results Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity alnylam.com ↗ |
| 2024-06-24 | Alnylam Pharmaceuticals | Results Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations alnylam.com ↗ |
| 2023-08-03 | Alnylam Pharmaceuticals | Results Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity alnylam.com ↗
Presented nine-month results from the randomized treatment extension period of the HELIOS-A study of vutrisiran in patients with they polyneuropathy of hATTR amyloidosis at the Italian Association for the Study of the Peripheral Nervous System |
| 2022-09-20 | Alnylam Pharmaceuticals | Regulatory Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy alnylam.com ↗
Today’s decision now means we can progress working with health authorities across Europe to achieve responsible and sustainable access arrangements that allow us to bring AMVUTTRA to patients as quickly as possible. |
| 2022-07-22 | Alnylam Pharmaceuticals | Regulatory Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy alnylam.com ↗ |
| 2022-06-13 | Alnylam Pharmaceuticals | Regulatory Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults alnylam.com ↗
The FDA approval of AMVUTTRA is based on positive 9-month results from HELIOS-A, a global, randomized, open-label, multicenter, Phase 3 study that evaluated the efficacy and safety of AMVUTTRA across a diverse group of patients with hATTR amyloidosis with polyneuropathy. |
| 2022-05-23 | Alnylam Pharmaceuticals | Results Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran alnylam.com ↗ |
| 2022-04-04 | Alnylam Pharmaceuticals | Regulatory Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran alnylam.com ↗ |
| 2022-02-10 | Alnylam Pharmaceuticals | Results Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity alnylam.com ↗
Reported Positive 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in hATTR Amyloidosis Patients with Polyneuropathy |
| 2022-01-21 | Alnylam Pharmaceuticals | Results Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy alnylam.com ↗ |
| 2021-10-27 | Alnylam Pharmaceuticals | Results Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy alnylam.com ↗
The final secondary endpoint, reduction in serum TTR levels with vutrisiran, demonstrated non-inferiority relative to the within-study patisiran arm, as expected. |
| 2021-09-13 | Alnylam Pharmaceuticals | Regulatory Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy alnylam.com ↗
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with polyneuropathy. |
| 2021-09-07 | Alnylam Pharmaceuticals | Results Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting alnylam.com ↗
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced additional positive results from subgroup analyses and exploratory endpoints of the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis. |
| 2021-08-03 | Alnylam Pharmaceuticals | Regulatory Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity alnylam.com ↗
Advanced Vutrisiran with New Drug Application (NDA) Submission to the U.S. Food and Drug Administration (FDA) for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis (hATTR-PN); Received FDA Acceptance of NDA with Prescription Drug User Fee Act (PDUFA) Date Set for April 14, 2022 |
| 2021-06-24 | Alnylam Pharmaceuticals | Regulatory Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis alnylam.com ↗
The FDA has set an action date of April 14, 2022 under the Prescription Drug User Fee Act (PDUFA), and the Agency has indicated that they are not currently planning an advisory committee meeting as part of the NDA review. |
| 2021-06-07 | Alnylam Pharmaceuticals | Results Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting alnylam.com ↗
Additional Results from Pre-specified Patient Subgroups Analysis Included with Encore Presentation of HELIOS-A Phase 3 Study of Investigational Vutrisiran |
| 2021-04-19 | Alnylam Pharmaceuticals | Results Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran alnylam.com ↗
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced full positive results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis, which met its primary and both secondary endpoints at nine months in patients with hereditary ATTR (hATTR) amyloidosis with polyneuropathy. |
| 2021-01-07 | Alnylam Pharmaceuticals | Results Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy alnylam.com ↗
Vutrisiran met the primary endpoint (p less than 0.001) and achieved statistically significant results (p less than 0.001) for each of the Norfolk QoL-DN and 10-MWT secondary endpoints. |
| 2020-04-14 | Alnylam Pharmaceuticals | Regulatory Alnylam Receives Fast Track Designation for Vutrisiran for the Treatment of the Polyneuropathy of hATTR Amyloidosis alnylam.com ↗
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to vutrisiran, an investigational therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. |
| 2018-06-04 | Alnylam Pharmaceuticals | Regulatory Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis alnylam.com ↗
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration ( FDA ) has granted Orphan Drug Designation to ALN-TTRsc02, an investigational RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis. |
| 2018-04-23 | Alnylam Pharmaceuticals | Regulatory Alnylam Receives Positive Opinion for Orphan Drug Designation in the European Union for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis alnylam.com ↗
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending ALN-TTRsc02, an investigational, subcutaneously administered RNAi therapeutic, for designation as an orphan medicinal product for the treatment of transthyretin (TTR)-mediated (ATTR) amyloidosis. |
| 2018-03-28 | Alnylam Pharmaceuticals | Results Alnylam Presents New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis alnylam.com ↗
In addition, the Company presented new data from the Phase 1 study of ALN-TTRsc02, an investigational, subcutaneously administered RNAi therapeutic in development for the treatment of ATTR amyloidosis. |
| 2016-12-16 | Alnylam Pharmaceuticals | Results Alnylam Presents Initial 2017 Pipeline Goals at R&D Day with Focus on Alnylam 2020 Strategy alnylam.com ↗
The Company also announced preliminary clinical data from its Phase 1 study of ALN-TTRsc02, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis. |
| 2015-10-14 | Alnylam Pharmaceuticals | Results Alnylam Demonstrates Continued Commitment to Transthyretin-Mediated Amyloidosis Patients with Advancement of ALN-TTRsc02, an Investigational RNAi Therapeutic with Potential for Low Volume, Once Quarterly, Subcutaneous Dose Regimen alnylam.com ↗
In pre-clinical studies, including those in non-human primates (NHPs), ALN-TTRsc02 achieved potent and highly durable knockdown of serum TTR of up to 99% with multi-month durability achieved after just a single dose, supportive of a potentially once quarterly dose regimen. |
All press releases naming this drug 56 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vutrisiran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07223203 ↗ |
| Known as | ALN-65492 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594511 ↗ |
| Known as | ALN-TTRSC02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02797847 ↗ |
| Known as | ALN-TTRSC02 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594511 ↗ |
| Known as | Votrisiran | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594511 ↗ |
| Action | Inhibit | “reduces hepatic production of transthyretin” PMID 37523143 ↗ Jul 2023 |
| Modality | Small interfering RNA (siRNA) | “Vutrisiran, a subcutaneously administered RNA interference (RNAi) therapeutic” PMID 37523143 ↗ Jul 2023 |
| Route | Subcutaneous | “Ascending doses of ALN-TTRSC02 by subcutaneous (SC) injection” NCT02797847 ↗ |
| Target | TTR | “TTR reduction with vutrisiran Q3M” PMID 35875890 ↗ Jul 2022 |